A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma and Reduced Therapy in Children With Medulloblastoma With Low-Risk Features
This study looks at ways to make treatment safer for children with a type of brain tumor called medulloblastoma. For average-risk patients, it tests if a medicine called sodium thiosulfate can protect against hearing loss caused by chemotherapy. For low-risk patients, it tests if giving less radiation can reduce side effects while still fighting the cancer effectively.
Children and young adults between 4 and 21 years old who have a newly diagnosed brain tumor called medulloblastoma can join. Participants must not have received prior radiation or chemotherapy, and pregnant individuals cannot take part. The tumor must not have spread (checked with brain and spine MRI and a spinal fluid test), central lab testing must show average-risk features or low-risk features (Group 4 with chromosome 11 loss), and children must enroll and be ready to start treatment within 31 days after surgery.
Participants will receive standard cancer treatments like surgery, chemotherapy, and radiation, with some receiving a special protective drug to prevent hearing loss. They will also undergo regular check-ups, hearing tests, imaging scans, and answer questionnaires about how they are feeling.
This study is currently recruiting patients at more than 100 hospitals in the United States and 5 in Canada. Your care team can help you find the closest participating hospital.
- 1Tests a protective medicine to prevent hearing loss from chemotherapy
- 2Explores using less radiation for low-risk patients to reduce side effects
- 3Open to newly diagnosed patients between 4 and 21 years old
Related videos
2Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.